HIV+ Liver Transplant for HIV Patients
Trial Summary
Will I have to stop taking my current medications?
The trial protocol does not specify if you need to stop taking your current medications. However, you must be willing to comply with all medications related to your transplant and HIV management.
What data supports the effectiveness of the HIV+ liver transplant treatment for HIV patients?
The study found that patient and graft survival rates for liver transplants from HIV-positive donors to HIV-positive recipients were better than historical data, with a 1-year survival rate of 83.3%. However, there was a potential increase in infections and cancer, which needs further investigation.12345
Is liver transplantation from HIV-positive donors to HIV-positive recipients safe?
Liver transplants from HIV-positive donors to HIV-positive recipients have shown similar patient and graft survival rates compared to those from HIV-negative donors, but there may be a higher risk of infections and cancer. Careful monitoring and management of drug interactions are important for safety.14567
How is the HIV+ liver transplant treatment different from other treatments for HIV patients?
This treatment is unique because it involves liver transplants from donors with HIV to recipients with HIV, which is not common practice. It is part of a pilot study under the HOPE Act, and while it shows promising survival rates, it may lead to more infections and cancer compared to transplants from non-HIV donors.12347
What is the purpose of this trial?
The primary objective of this study is to determine if an HIV-infected donor liver (HIVD+) transplant is safe with regards to major transplant-related and HIV-related complications
Research Team
Christine Durand, MD
Principal Investigator
Johns Hopkins University
Eligibility Criteria
This trial is for adults over 18 with HIV who need a liver transplant and meet standard criteria, including managing their HIV effectively (low viral load) and having no active opportunistic infections. They must understand the study, agree to follow treatment plans, use contraception, and not be significantly underweight due to HIV.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Transplantation
Participants receive a liver transplant from either an HIV-infected or HIV-uninfected deceased donor
Follow-up
Participants are monitored for safety and effectiveness after transplant, including monitoring for HIV breakthroughs and graft function
Observational Follow-up
Participants in the observational group are followed with limited data collection
Treatment Details
Interventions
- HIVD+/R+
Find a Clinic Near You
Who Is Running the Clinical Trial?
Johns Hopkins University
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator